EBiSC2 builds on the achievements of the European Bank for hiPSCs, giving academic and commercial researchers access to high quality hiPSCs from diverse disease and genetic backgrounds (cells.ebisc.org). Supported by the Innovative Medicines Initiative 2 (IMI2 JU), a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), key partners of the initial EBiSC project are joining forces to build on EBiSC’s existing assets and establish EBiSC2 as a self-sustainable central bank for hiPSC lines, focused on satisfying user requirements.
Launched on 1st March 2019 and focussed on the needs of the research community and scientific excellence, EBiSC2 will continue to distribute disease-relevant and high quality hiPSCs with freedom to operate for research, along with comprehensive datasets. Additional services such as bulk production of hiPSCs and delivery of pre-differentiated cell populations will be established to facilitate the use of hiPSC in research.
As integral partner, Bioneer will carry on to produce high-quality iPS cells and contribute to the ever growing selection of advanced disease models present in the EBiSC repository. If you want to know more about the IMI-project, or have your own iPSC/gene editing query in mind, please feel free to contact R&D Manager Bjørn Holst via email or call +45 45 160 444.
To get an overview of Bioneer’s capabilities in the field, follow the link.
To read the press release, press here.
To read more about Bioneer’s role in EBiSC1 and 2, read the latest edition of the LIFE SCIENCE / DANSK BIOTEK magazine here, pages 16-17.